EP1552298A4 - RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF - Google Patents

RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF

Info

Publication number
EP1552298A4
EP1552298A4 EP03762330A EP03762330A EP1552298A4 EP 1552298 A4 EP1552298 A4 EP 1552298A4 EP 03762330 A EP03762330 A EP 03762330A EP 03762330 A EP03762330 A EP 03762330A EP 1552298 A4 EP1552298 A4 EP 1552298A4
Authority
EP
European Patent Office
Prior art keywords
cytokins
organs
restoring
tissues
protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03762330A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1552298A2 (en
Inventor
Jacob Nielsen
Jan Torleif Pedersen
Jens Gerwien
Katrine Bay
Lars Ostergaard Pedersen
Marcel Leist
Marie Aavang Geist
Pekka Kallunki
Soren Christensen
Thomas Sager
Michael Brines
Anthony Cerami
Carla Cerami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Warren Kenneth S Institute Inc
Original Assignee
H Lundbeck AS
Warren Kenneth S Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS, Warren Kenneth S Institute Inc filed Critical H Lundbeck AS
Publication of EP1552298A2 publication Critical patent/EP1552298A2/en
Publication of EP1552298A4 publication Critical patent/EP1552298A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
EP03762330A 2002-07-01 2003-07-01 RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF Withdrawn EP1552298A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39245502P 2002-07-01 2002-07-01
US392455P 2002-07-01
US39342302P 2002-07-03 2002-07-03
US393423P 2002-07-03
PCT/US2003/020964 WO2004003176A2 (en) 2002-07-01 2003-07-01 Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs

Publications (2)

Publication Number Publication Date
EP1552298A2 EP1552298A2 (en) 2005-07-13
EP1552298A4 true EP1552298A4 (en) 2006-11-08

Family

ID=30003253

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03762330A Withdrawn EP1552298A4 (en) 2002-07-01 2003-07-01 RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF

Country Status (15)

Country Link
US (1) US20040122216A1 (pl)
EP (1) EP1552298A4 (pl)
JP (1) JP2006507228A (pl)
KR (1) KR20060019501A (pl)
AU (1) AU2003251770B9 (pl)
BR (1) BR0312395A (pl)
CA (1) CA2491567A1 (pl)
EA (1) EA010200B1 (pl)
IL (1) IL166066A0 (pl)
IS (1) IS7604A (pl)
MX (1) MXPA05000063A (pl)
NO (1) NO20050504L (pl)
NZ (1) NZ537306A (pl)
PL (1) PL374580A1 (pl)
WO (1) WO2004003176A2 (pl)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PT1465987E (pt) 2001-12-07 2008-04-15 Crucell Holland Bv Produção de vírus, isolados virais e vacinas
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20060216757A1 (en) * 2003-04-25 2006-09-28 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2004099396A1 (en) 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
WO2005032467A2 (en) * 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2006061853A2 (en) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Novel erythropoietic compounds and a process for producing erythropoietic compounds
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
CN102512665A (zh) * 2005-06-01 2012-06-27 新潟Tlo株式会社 含有epo衍生物的血液相关疾病的治疗剂
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
WO2007060213A2 (en) * 2005-11-24 2007-05-31 Laboratoires Serono S.A. Erythropoietin polypeptides and uses thereof
WO2008058942A2 (en) * 2006-11-13 2008-05-22 Charite - Universitätsmedezin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
MX2009007139A (es) 2006-12-28 2009-10-08 Centocor Ortho Biotech Inc Metodos y vectores para generar inmunoglobulinas no sialiladas.
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
WO2009102021A1 (ja) * 2008-02-14 2009-08-20 Kyoto University 骨髄由来幹細胞、前駆細胞機能賦活による網膜疾患治療
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012046238A2 (en) * 2010-10-06 2012-04-12 Ramot At Tel-Aviv University Ltd. Erythropoietin receptor antagonists
WO2012097256A1 (en) * 2011-01-14 2012-07-19 University Of Tennessee Research Foundation Therapeutic compositions and methods for disorders associated with neuronal degeneration
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CN104968354A (zh) * 2011-12-21 2015-10-07 现代治疗公司 增加器官或器官外植体的活力或寿命的方法
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013158871A1 (en) * 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10831013B2 (en) 2013-08-26 2020-11-10 S.D. Sight Diagnostics Ltd. Digital microscopy systems, methods and computer program products
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
SI2970413T1 (sl) 2014-04-01 2018-10-30 Swedish Orphan Biovitrum Ab (Publ) Modificirana sulfamidaza in proizvodja le-te
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2016322966B2 (en) 2015-09-17 2021-10-14 S.D. Sight Diagnostics Ltd Methods and apparatus for detecting an entity in a bodily sample
US11733150B2 (en) * 2016-03-30 2023-08-22 S.D. Sight Diagnostics Ltd. Distinguishing between blood sample components
EP3455626B1 (en) 2016-05-11 2025-08-06 S.D. Sight Diagnostics Ltd. Performing optical measurements on a sample
US11307196B2 (en) 2016-05-11 2022-04-19 S.D. Sight Diagnostics Ltd. Sample carrier for optical measurements
RU2647570C1 (ru) * 2016-06-29 2018-03-16 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Генетическая конструкция для экспрессии функционально-активного человеческого стресс-белка (БТШ70) с мутированными сайтами гликозилирования для наработки в эукариотических экспрессионных системах
KR101719355B1 (ko) * 2016-11-14 2017-03-27 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2018369859B2 (en) 2017-11-14 2024-01-25 S.D. Sight Diagnostics Ltd Sample carrier for optical measurements
AR113091A1 (es) 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
RU2744453C2 (ru) * 2019-09-02 2021-03-09 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний
CU24704B1 (es) * 2019-09-05 2024-04-08 Ct Inmunologia Molecular Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso
AU2020372024B2 (en) 2019-10-22 2026-03-12 S.D. Sight Diagnostics Ltd Accounting for errors in optical measurements
BR112022011312A2 (pt) 2019-12-12 2022-08-23 S D Sight Diagnostics Ltd Análise de um analito disposto dentro de um meio
AU2020400400B2 (en) 2019-12-12 2026-03-19 S.D. Sight Diagnostics Ltd Detecting platelets in a blood sample
MX2022007127A (es) 2019-12-12 2022-07-11 S D Sight Diagnostics Ltd Generacion artificial de una imagen de frotis sanguineo en color.
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024160A2 (en) * 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
EP0640619A1 (en) * 1993-08-17 1995-03-01 Amgen Inc. Erythropoietin analogs with additional glycosylation sites
EP0668351A1 (en) * 1989-10-13 1995-08-23 Amgen Inc. Erythropoietin isoforms
US5457089A (en) * 1989-07-20 1995-10-10 Behringwerke Aktiengesellschaft Muteins of human erythropoietin, the preparation thereof and the use thereof
WO1997008307A1 (en) * 1995-08-24 1997-03-06 Il Dong Pharmaceutical Co., Ltd. Heterologous protein production system using avian cells
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO2000024893A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
WO2000061164A1 (en) * 1999-04-13 2000-10-19 Kenneth S. Warren Laboratories Modulation of excitable tissue function by peripherally administered erythropoietin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5625035A (en) * 1992-06-05 1997-04-29 The Regents, University Of California Erythropoietin binding protein from mammalian serum
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
BR9406490A (pt) * 1993-04-29 1996-03-05 Abbott Lab Análogo de eritropoietina humana,DNA de filamento duplo,vetor de expressão célula de mamiferos em cultura composição farmaceutica segundo e terceiro análogo de eritropoietina humana e processos para fabricar um segundo análogo de eritropoietina e para usar um segundo análogo
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5835382A (en) * 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
JP2001507215A (ja) * 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JP2004528001A (ja) * 2000-05-12 2004-09-16 ネオーズ テクノロジーズ， インコーポレイテッド インビトロにおけるフコシル化組換えグリコペプチド
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457089A (en) * 1989-07-20 1995-10-10 Behringwerke Aktiengesellschaft Muteins of human erythropoietin, the preparation thereof and the use thereof
EP0668351A1 (en) * 1989-10-13 1995-08-23 Amgen Inc. Erythropoietin isoforms
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO1994024160A2 (en) * 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
EP0640619A1 (en) * 1993-08-17 1995-03-01 Amgen Inc. Erythropoietin analogs with additional glycosylation sites
WO1997008307A1 (en) * 1995-08-24 1997-03-06 Il Dong Pharmaceutical Co., Ltd. Heterologous protein production system using avian cells
WO2000024893A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
WO2000061164A1 (en) * 1999-04-13 2000-10-19 Kenneth S. Warren Laboratories Modulation of excitable tissue function by peripherally administered erythropoietin

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRINES M L ET AL: "ERYTHROPOIETIN CROSSES THE BLOOD-BRAIN BARRIER TO PROTECT AGAINST EXPERIMENTAL BRAIN INJURY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 19, 12 September 2000 (2000-09-12), pages 10526 - 10531, XP001148014, ISSN: 0027-8424 *
CAMPANA W M ET AL: "Identification of a neurotrophic sequence in erythropoietin", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS, ATHENS, GR, vol. 1, no. 1, January 1998 (1998-01-01), pages 235 - 241, XP001064780, ISSN: 1107-3756 *
DONG Y J ET AL: "Receptor Binding of Asialoerythropietin", JOURNAL OF CELLULAR BIOCHEMISTRY, LISS, NEW YORK, NY, US, vol. 48, no. 3, March 1992 (1992-03-01), pages 269 - 276, XP002997169, ISSN: 0730-2312 *
ERBYRAKTAR S ET AL: "ASIALOERYTHROPOIETIN IS A NONERYTHROPOIETIC CYTOKINE WITH BROAD NEUROPROTECTIVE ACTIVITY IN VIVO", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 11, 27 May 2005 (2005-05-27), pages 6741 - 6746, XP009070746, ISSN: 0027-8424 *
FUKUDA M N ET AL: "SURVIVAL OF RECOMBINANT ERYTHROPOIETIN IN THE CURCULATION: THE ROLEOF CARBOHYDRATES", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 73, no. 1, January 1989 (1989-01-01), pages 84 - 89, XP000199651, ISSN: 0006-4971 *
LEIST M ET AL: "DERIVATIVES OF ERYTHROPOIETIN THAT ARE TISSUE PROTECTIVE BUT NOT ERYTHROPOIETIC", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 305, no. 5681, 9 July 2004 (2004-07-09), pages 239 - 243, XP002346906, ISSN: 0036-8075 *
MUN KYO-CHEOL ET AL: "Impaired biological activity of erythropoietin by cyanate carbamylation", CA, 2000, XP002346922 *

Also Published As

Publication number Publication date
NZ537306A (en) 2008-11-28
IS7604A (is) 2004-12-17
WO2004003176A3 (en) 2004-10-28
JP2006507228A (ja) 2006-03-02
IL166066A0 (en) 2006-01-15
KR20060019501A (ko) 2006-03-03
AU2003251770B2 (en) 2009-05-07
WO2004003176A2 (en) 2004-01-08
EP1552298A2 (en) 2005-07-13
PL374580A1 (pl) 2005-10-31
US20040122216A1 (en) 2004-06-24
CA2491567A1 (en) 2004-01-08
AU2003251770B9 (en) 2009-06-04
WO2004003176A9 (en) 2008-02-07
BR0312395A (pt) 2007-06-19
MXPA05000063A (es) 2005-04-08
NO20050504L (no) 2005-03-22
EA010200B1 (ru) 2008-06-30
EA200500120A1 (ru) 2005-12-29
AU2003251770A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
EP1552298A4 (en) RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
IL166067A0 (en) Tissue protective cytokines for the protection restoration and enhancement of responsive cells tissues and organs
EP1156755A4 (en) ALDEHYDE AND GLYCOSIDASE TREATED SOFT AND BONE WEBSITE XENOTRANE PLANTS
EE200300267A (et) Erütropoetiinile reageerivate rakkude, kudede ja elundite kaitsmine, taastamine ja tugevdamine
AU2002340122A1 (en) Pathological tissue detection and treatment employing targeted benzoindole optical agents
AU5493598A (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
EP1625140A4 (en) BRANCHED IMMUNOMODULAR COMPOUNDS AND METHOD OF USE THEREOF
AU2002322752A1 (en) Cooled tip laser catheter for sensing and ablation of cardiac tissue
EE200200291A (et) Kaitse kiht kehasisesesse luumenisse viidava anduri kaitsmiseks ja kaitsekihi valmistamise meetod
AU4180900A (en) Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
TW388280U (en) Improved structure of protection pad for goggles
AU2406299A (en) Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
EP1535514A4 (en) COMPOSITION FOR THE PROTECTION OF ORGANS, TISSUE OR CELLS AND THEIR USE
FI963132A7 (fi) Diastereomeerisesti puhtaat trifluorimetyyliketonipeptidijohdannaiset ihmisen leukosyyttielastaasin inhibiittoreina
DE10084458T1 (de) Absorptionsfähige Gewebe zur Verbesserung der Hautschutzschicht
IL138221A0 (en) Formulations for protection of peg-interferon alpha conjugates
EP1497314A4 (en) COMPOSITIONS AND METHODS OF USE ON PEPTIDES AGAINST PLACENTA AND FAT FABRICS
EP1505871A4 (en) PRESERVATION OF RNA AND MORPHOLOGY IN CELLS AND TISSUE
AU2003215078A1 (en) Prevention of transgene escape in genetically modified perennials
ITMI980333U1 (it) Struttura perfezionata di suola adatta alla traspirazione
ITMI20021417A0 (it) Apparecchio per l'asportazione di calli duroni e simili dall'epidermide
EP1231262A4 (en) METHODS FOR VITRO CULTIVATION OF LYMPHOCYTES AND COMPOSITIONS FOR GENE THERAPY
EP1459756A4 (en) DISTANCE PHOTO MOTOR AND INHIBITORS FOR APOPTOSIS CELLS IN VIVO
EP1218393A4 (en) CELL-TARGETED COMPOSITIONS AND METHODS FOR THE USE THEREOF
AU2002367374A1 (en) Expression and purification of atm protein using vaccinia virus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050128

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20061006

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CERAMI, CARLA

Inventor name: CERAMI, ANTHONY

Inventor name: BRINES, MICHAEL

Inventor name: SAGER, THOMAS

Inventor name: CHRISTENSEN, SOREN

Inventor name: KALLUNKI, PEKKA

Inventor name: GEIST, MARIE, AAVANG

Inventor name: LEIST, MARCEL

Inventor name: PEDERSEN, LARS, OSTERGAARD

Inventor name: BAY, KATRINE

Inventor name: GERWIEN, JENS

Inventor name: PEDERSEN, JAN, TORLEIF

Inventor name: NIELSEN, JACOB

17Q First examination report despatched

Effective date: 20070724

R17D Deferred search report published (corrected)

Effective date: 20070823

R17D Deferred search report published (corrected)

Effective date: 20080207

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130201